ATI-450 – pancreatic cancer. darolutamide – metastatic hormone sensitive prostate cancer. mirvetuximab soravtansine – in ovarian cancer. KB-0742 – in MYC-amplified solid tumors. zandelisib – in relapsed/refractory follicular lymphoma. OP-1250 – in ≥4-line ER+/HER2-negative breast cancer.
Compendium (d) Compendium (f)
Startseite
Kongressberichte 2017
59th ASH Annual Meeting and Exposition
Interviews
Statement Thorsten Zenz, Zürich
Startseite
Kongressberichte 2017
59th ASH Annual Meeting and Exposition
Interviews
Statement Thorsten Zenz, Zürich